InvestorsHub Logo
Followers 30
Posts 2792
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Saturday, 12/05/2020 1:22:47 PM

Saturday, December 05, 2020 1:22:47 PM

Post# of 48
NTLA 5001, a T Cell Product Candidate with CRISPR Based Targeted Insertion of a High Avidity, Natural, WT1 Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL https://3o5c4w3neipl16yvhj3nfqam-wpengine.netdna-ssl.com/wp-content/uploads/Intellia-ASH-Poster-Presentation_12.05.2020.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NTLA News